Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celgene Corporation

Related CELG
Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks
3 Companies Investing In Stem Cell Research
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $91.00 to $94.00.

Jefferies noted, “CELG announced Abraxane met its overall survival primary endpoint in its Phase 3 pancreatic cancer study. We have long considered this indication to be risky and upside to our valuation. Adding pancreatic cancer to our valuation raises our price target from $91 to $94.”

Celgene Corporation closed on Friday at $71.50.

Latest Ratings for CELG

DateFirmActionFromTo
Sep 2014Cantor FitzgeraldMaintainsBuy
Sep 2014SunTrust Robinson HumphreyInitiates Coverage on
Jul 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters